Hyperglycemia acutely lowers the postprandial excursions of glucagon-like peptide-1 and gastric inhibitory polypeptide in humans

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1379-1385

  Vollmer, Kirsten ^a   Gardiwal, Husai ^a   Menge, Bjoern A ^a   Goetze, Oliver ^a   Deacon, Carolyn F ^b   Schmidt, Wolfgang E ^a   Holst, Jens J ^b   Meier, Juris J ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CARBON 13; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; OCTANOIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HYPERGLYCEMIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH EMPTYING;

EID: 65249174637     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2197     Document Type: Article

References (47)

1. Creutzfeldt W 1979 The incretin concept today. Diabetologia 16:75-85
2. Meier JJ, Nauck MA 2005 Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev 21:91-117
3. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
4. Nauck MA, Kleine N, øhrskov C, Holst JJ, Willms B, Creutzfeldt W 1993 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
5. VerdichC, FlintA,GutzwillerJP,NaslundE, BeglingerC,HellstromPM, Long SJ, Morgan LM, Holst JJ, Astrup A 2001 A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382-4389
6. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ 1993 Truncated GLP-1 (proglucagon78-107-amide) inhibitsgastricandpan- creatic functions in man. Dig Dis Sci 38:665-673
7. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA 2003 Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725
8. Meier JJ, Goetze O, Anstipp J, Hagemann D, Holst JJ, Schmidt WE, Gallwitz B, Nauck MA 2004 Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am JPhysiol (Endocrinol Metab) 286:E621-E625
9. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA 2003 Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
10. ørskov C, Wettergen A, Holst JJ 1996 Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31:665-670
11. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723
12. Nauck MA, Bartels E, ørskov C, Ebert R, Creutzfeldt W 1993 Additive in- sulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. JClin Endocrinol Metab 76:912-917
13. Nauck MA,Homberger E, Siegel EG, Allen RC, Eaton RP,Ebert R, Creutzfeldt W 1986 Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. JClin Endocrinol Metab 63:492-498
14. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W 1986 Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-54
15. Nauck MA, Heimesaat MM,Orskov C,Holst JJ,Ebert R,Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetichumangastricinhibitorypolypeptideinpatientswithtype-2 diabetes mellitus. JClin Invest 91:301-307
16. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA 2001 Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50:2497-2504
17. Vilsbøll T, Krarup T, Madabad S, Holst JJ 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45:1111-1119
18. Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE, Nauck MA 2004 Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 53 (Suppl 3): S220-S224
19. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ 2001 Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
20. Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ 2008 Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678-687
21. Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA 2005 Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia 48:1872-1881
22. Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ 2004 Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 122:209-217
23. Nauck MA, Baller B, Meier JJ 2004 Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53(Suppl3):S190 -S196
24. Meier JJ, Kemmeries G, Holst JJ, Nauck MA 2005 Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54:2212-2218
25. Gentilcore D, Chaikomin R, Jones KL, Russo A, Feinle-Bisset C, Wishart JM, Rayner CK, Horowitz M 2006 Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 91:2062-2067
26. O'Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM, Morris HA, Horowitz M 2004 Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 89:3431-3435
27. Horowitz M, O'Donovan D, Jones KL,Feinle C, Rayner CK, Samsom M 2002 Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 19:177-194
28. Deacon CF, Johnsen AH, Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
29. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
30. Holst JJ 1997 Enteroglucagon. Annu Rev Physiol 59:257-271
31. Meier JJ, GethmannA, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA 2006 Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49:452-458
32. Ghoos YE, Maes BD, Gaypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G 1993 Measurement ofgastric emptying rate of solids by means ofa carbon labeled octanoic acid breath test. Gastroenterology 104:1640-1647
33. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439
34. Nauck MA, Baller B, Meier JJ 2004 Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53(Suppl3):S190-S196
35. Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, Holst JJ, Krarup T 2007 Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56:1951-1959
36. Elahi D, Andersen DK, Muller DC, Tobin JD, Brown JC, Andres R 1984 The enteric enhancement of glucose-stimulated insulin release. The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus. Diabetes 33:950-957
37. Ebert R, Creutzfeldt W 1980 Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 19:198-204
38. Ebert R, Creutzfeldt W 1980 Decreased GIP secretion through impairment of absorption. In: Wimersma Greidanus TB, ed. Frontiers in Hormone Research. Basel, Switzerland: S. Karger; 192-201
39. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, Kim HH, Xu X, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM 2007 Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104:15069-15074
40. Vilsbøll T, Agersø H, Krarup T, Holst JJ 2003 Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224
41. Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsboll T 2006 Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 155:485-493
42. Ebert R, Creutzfeldt W 1980 Hypo- and hypersecretion of GIP in maturity- onset diabetics. Diabetologia 19:271-272
43. Hojberg PV, Vilsboll T, Zander M, Knop FK, Volund A, Krarup T, Holst JJ, Madsbad S 2006 4-weeks of near-normalisation of blood glucose has no effect on postprandial GLP-1 secretion but enhances β-cell responsiveness during a meal in patients with type 2 diabetes. Diabetes 49(Suppl 1):A0664 (Abstract)
44. Unger R, Agiular-Parada E,Müller W,Eisentraut A 1970 Studies of pancreatic a-cell function in normal and diabetic subjects. J Clin Invest 49:837-848
45. SamolsE, StagnerJI, EwartRB, Marks V1988 The order ofisletmicrovascular cellular perfusion is B-A-D in the perfused rat pancreas. J Clin Invest 82:350 -353
46. Ravier MA, Rutter GA 2005 Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic α-cells. Diabetes 54:1789-1797
47. Meier JJ, Kjems LL, Veldhuis JD, Lefebvre P, Butler PC 2006 Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis. Diabetes 55:1051-1056